Seraphina Therapeutics, Inc.

Seraphina Therapeutics, Inc. is a health and wellness company founded in 2017 by Stephanie Venn-Watson, Eric Venn-Watson, Kim Kamdar, and Nicholas Schork, with its headquarters located in San Diego, California. The company focuses on advancing global health through the discovery and development of essential fatty acids and micronutrient therapeutics, leveraging metabolomics and nutritional science to create evidence-based consumer products. Business/Product Breakdown Seraphina Therapeutics develops fatty acid supplements, food fortifiers, and nutritional interventions aimed at strengthening cells, supporting mitochondrial function, and promoting cellular homeostasis to counter age-related breakdown. Its flagship product, Fatty15, is a vegan-friendly, pure C15:0 (pentadecanoic acid) supplement, recognized as the first essential fatty acid discovered in over 90 years, found in trace amounts in whole dairy fat, certain fish, and plants. This supplement targets Cellular Fragility Syndrome, a nutritional C15:0 deficiency potentially affecting one in three people globally, linked to increased risks of type 2 diabetes, heart disease, and nonalcoholic fatty liver disease. The company's FA15 ingredient has achieved Generally Recognized as Safe (GRAS) status, allowing its use in plant-based milks, meats, and nutritional bars up to 245 mg per day. Seraphina also offers an at-home Fatty15 C15:0 Test in partnership with Genova Diagnostics to measure C15:0 levels. Additionally, the company is developing STI-100, a lipid-based therapeutic in preclinical stages for cardiometabolic diseases, showing efficacy in reducing glucose, insulin, and cholesterol. Seraphina holds exclusive licensing rights to over 30 U.S. and international patents for C15:0 commercialization, including its use as a supplement, food fortifier, and pharmaceutical.